Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 7,415 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average cost of $2.70 per share, for a total transaction of $20,020.50. Following the acquisition, the insider now directly owns 353,311 shares of the company's stock, valued at $953,939.70. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.
Brett Matthew Hall also recently made the following trade(s):
- On Monday, June 23rd, Brett Matthew Hall purchased 6,007 shares of Immuneering stock. The stock was bought at an average cost of $2.43 per share, with a total value of $14,597.01.
Immuneering Stock Up 14.5%
Immuneering stock traded up $0.36 during mid-day trading on Tuesday, hitting $2.80. The company's stock had a trading volume of 523,400 shares, compared to its average volume of 2,511,205. The stock's fifty day moving average price is $1.64 and its two-hundred day moving average price is $1.75. The stock has a market capitalization of $100.59 million and a P/E ratio of -1.39. Immuneering Corporation has a twelve month low of $1.00 and a twelve month high of $3.83.
Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). Equities analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current year.
Hedge Funds Weigh In On Immuneering
Several hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Immuneering in the 1st quarter worth approximately $32,000. HighTower Advisors LLC raised its holdings in Immuneering by 17.7% in the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock valued at $128,000 after acquiring an additional 12,600 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after purchasing an additional 10,126 shares in the last quarter. Tang Capital Management LLC acquired a new position in shares of Immuneering in the fourth quarter valued at $27,000. Finally, Southport Management L.L.C. boosted its stake in Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock worth $473,000 after buying an additional 10,000 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on IMRX shares. Oppenheimer lowered their target price on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday, June 18th. Mizuho lifted their price target on shares of Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Wednesday, June 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $9.00 price objective on shares of Immuneering in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Immuneering presently has an average rating of "Moderate Buy" and an average target price of $13.25.
Get Our Latest Stock Analysis on Immuneering
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
